GENE ONLINE|News &
Opinion
Blog

2021-02-17| R&DStartups

George Church’s New Startup Engineers AAV Vectors that Evades Host Immune Responses

by Rajaneesh K. Gopinath
Share To
Adeno-associated viral (AAV) vectors are widely used in vivo therapeutic gene delivery vehicles. The many advantages they provide, including safety, broad tissue tropism, lack of pathogenicity, and efficient and persistent gene transfer, have made them the "gold standard" for gene therapies.

GO Prime with only $1.49 now

LATEST
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
2024-09-04
Alnylam Pharma Shares Dip Despite Positive Phase 3 HELIOS-B Heart Disease Results
2024-09-04
EVENT
2024-09-11
2024 Bio Asia Pacific
Bangkok, Thailand
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top